Epoetin beta biosimilar (Pharmapark)

促红素β生物类似药 (Pharmapark)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEpoetin beta biosimilar (Pharmapark)
Drug Alias Name依泊汀β生物仿制药 (Pharmapark)促红素β生物仿制药 (Pharmapark)倍他依泊汀生物仿制药 (Pharmapark)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionErythropoiesis stimulantsErythropoietin receptor agonists
TargetsErythropoietin receptor
Therapy Area/IndicationsAnemia
Global Approved IndicationsAnemia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2007/12/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPharmapark
China Registration ClassN/A

Develop Information

Active CompaniesPharmapark
Inactive CompaniesN/A
Active IndicationsAnemia
Inactive IndicationsN/A

Other Information

ATC CodeB03XA01
Related LinksN/A